{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:42:27Z","timestamp":1792078947868,"version":"4.4.0"},"reference-count":120,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Psoriasis is a chronic, inflammatory skin disease occurring worldwide that significantly affects patients\u2019 quality of life. This common skin condition is characterized by abnormal hyperplasia of keratinocytes, which leads to the formation of raised, scaly plaques, typically located on the head, elbows, knees, and lumbar region. Psoriasis usually requires long-term drug therapy, which aims not only to combat skin symptoms but also to improve quality of life. Although topical treatments, systemic treatments (methotrexate, cyclosporine, acitretin), and phototherapy play a role, biologic agents have improved the efficacy of treatment of moderate-to-severe psoriasis. The purpose of this article is to comprehensively review the clinical trial data and evaluate and compare the key features of the currently approved biologic drugs for the treatment of psoriasis.<\/jats:p>","DOI":"10.3390\/ph19020340","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:00:52Z","timestamp":1771840852000},"page":"340","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biological Treatment of Psoriasis\u2014Data So Far"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-4001","authenticated-orcid":false,"given":"Mateusz","family":"Matwiejuk","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4936-3120","authenticated-orcid":false,"given":"Agnieszka","family":"Mik\u0142osz","sequence":"additional","affiliation":[{"name":"Department of Physiology, Medical University of Bialystok, Bialystok, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1948-0545","authenticated-orcid":false,"given":"Hanna","family":"My\u015bliwiec","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7407-8156","authenticated-orcid":false,"given":"Adrian","family":"Chabowski","sequence":"additional","affiliation":[{"name":"Department of Physiology, Medical University of Bialystok, Bialystok, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5923-910X","authenticated-orcid":false,"given":"Iwona","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National regional worldwide epidemiology of psoriasis: Systematic analysis modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000455840","article-title":"Psoriasis and Obesity","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Caiazzo, G., Fabbrocini, G., Di Caprio, R., Raimondo, A., Scala, E., Balato, N., and Balato, A. (2018). Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01668"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e3676","DOI":"10.1097\/MD.0000000000003676","article-title":"Association of Serum Uric Acid Levels in Psoriasis: A Systematic Review and Meta-Analysis","volume":"95","author":"Li","year":"2016","journal-title":"Medicine"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liu, L., Sun, X., Li, H., Wang, Y., Zhou, M., Hua, L., Li, B., and Li, X. (2021). Updated Evidence of the Association Between Elevated Serum Uric Acid Level and Psoriasis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.645550"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Li, X., Kong, L., Li, F., Chen, C., Xu, R., Wang, H., Peng, S., Zhou, M., and Li, B. (2015). Association between Psoriasis and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145221"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Holmannova, D., Borsky, P., Borska, L., Andrys, C., Hamakova, K., Rehacek, V., Svadlakova, T., Malkova, A., Beranek, M., and Palicka, V. (2020). Metabolic Syndrome, Clusterin and Elafin in Patients with Psoriasis Vulgaris. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165617"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: A brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"key":"ref_10","unstructured":"Baker, B.S. (2008). From Arsenic to Biologicals: A 200 Year History of Psoriasis, Garner Press."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/jid.1952.72","article-title":"The effect of topically applied compound F in selected dermatoses","volume":"19","author":"Sulzberger","year":"1952","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/00000441-195102000-00009","article-title":"Therapeutic suppression of tissue reactivity. II Effect of aminopterine in rheumatoid arthritis and psoriasis","volume":"221","author":"Gubner","year":"1951","journal-title":"Am. J. Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjd.14816","article-title":"British Association of Dermatologists\u2019 guidelines for the safe and effective prescribing of methotrexate for skin disease 2016","volume":"175","author":"Warren","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_14","first-page":"385","article-title":"Zur dermatologischen Therapie von Dermatosen mit langwelligem UV nach Photosensibilisierung der Haut mit Methoxsalen. Erste Ergebnisse bei der Psoriasis vulgaris [Dermatological therapy of dermatoses using long-wave UV following methoxsalen photosensitization of the skin. First results in psoriasis vulgaris]","volume":"48","author":"Tronnier","year":"1973","journal-title":"Z. Haut Geschlkr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjd.14317","article-title":"British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015","volume":"174","author":"Ling","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJM197909063011015","article-title":"Cyclosporin A for psoriasis","volume":"301","author":"Mueller","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2133.1993.tb00234.x","article-title":"The effect of short- term lowdose cyclosporin on renal function and blood pressure in patients with psoriasis","volume":"128","author":"Brown","year":"1993","journal-title":"Br. J. Dermatol."},{"key":"ref_18","first-page":"225","article-title":"Transcriptional control of epidermal growth factor receptor by retinoic acid","volume":"3","author":"Zheng","year":"1992","journal-title":"Cell Growth Differ."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1468-3083.1993.tb00058.x","article-title":"Acitretin in combination with PUVA: A randomized double-blind placebo-controlled study in severe psoriasis","volume":"2","author":"Sommerburg","year":"1993","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","first-page":"39","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1331\/154434503322452328","article-title":"Alefacept, first biologic agent approved for treatment of psoriasis","volume":"43","author":"Piascik","year":"2003","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1468-3083.17.s2.4.x","article-title":"Clinical response to alefacept: Results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis","volume":"17","author":"Krueger","year":"2003","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","unstructured":"(2026, February 18). Clinical and Research Information on Drug-Induced Liver Injury [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548345\/."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"R\u00f8nholt, K., and Iversen, L. (2017). Old and New Biological Therapies for Psoriasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112297"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wadhwa, M., Bird, C., Atkinson, E., Cludts, I., and Rigsby, P. (2021). The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.636420"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1515\/rir-2024-0006","article-title":"Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation","volume":"5","author":"Ciccia","year":"2024","journal-title":"Rheumatol. Immunol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00403-024-03520-0","article-title":"Impact of adalimumab on erectile dysfunction, sperm parameters and hormonal profile in male psoriasis patients: A six-month observational study","volume":"317","author":"Kartal","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/bjd\/ljad179","article-title":"Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"189","author":"Alabas","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jamadermatol.2014.5479","article-title":"Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment","volume":"151","author":"Menting","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm939","article-title":"Lasker Clinical Medical Research Award. TNF is defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases","volume":"9","author":"Feldmann","year":"2003","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Narbutt, J., Jakubczak, Z., Wasiewicz-Ciach, P., Wojtania, J., Krupa, K., Sobolewska-Sztychny, D., Ci\u0105\u017cy\u0144ska, M., Ko\u0142t-Kami\u0144ska, M., Reich, A., and Skibi\u0144ska, M. (2024). Effectiveness and Safety of Etanercept in Paediatric Patients with Plaque-Type Psoriasis: Real-World Evidence. J. Clin. Med., 13.","DOI":"10.3390\/jcm13164858"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/exd.14835","article-title":"Transcriptomic responses of peripheral blood mononuclear cells to cyclosporin and etanercept in a female infant with juvenile generalized pustular psoriasis","volume":"32","author":"Lin","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s10620-024-08380-2","article-title":"Some Drugs Have Two Faces: Paradoxical Colitis in a Patient with Psoriatic Arthritis Previously Treated with Etanercept and IL-17 Inhibitors","volume":"69","author":"Huynh","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lee, J.U., Shin, W., Son, J.Y., Yoo, K.Y., and Heo, Y.S. (2017). Molecular Basis for the Neutralisation of Tumour Necrosis Factor \u03b1 by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010228"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s13555-024-01210-3","article-title":"Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study","volume":"14","author":"Korge","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"T51","DOI":"10.1016\/j.farma.2023.11.004","article-title":"Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol","volume":"48","author":"Ruiz","year":"2024","journal-title":"Farm. Hosp."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Coto-Segura, P., Seg\u00fa-Verg\u00e9s, C., Martorell, A., Moreno-Ram\u00edrez, D., Jorba, G., Junet, V., Guerri, F., Daura, X., Oliva, B., and Cara, C. (2023). A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1212981"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2024.04.045","article-title":"A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis","volume":"91","author":"Feldman","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2321188","DOI":"10.1080\/09546634.2024.2321188","article-title":"Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients","volume":"35","author":"Li","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2241941","DOI":"10.1080\/09546634.2023.2241941","article-title":"Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience","volume":"34","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kong, L., Huang, D., Lu, J., Zhang, Y., Li, Y., Yi, X., and Shi, Y. (2023). Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: A case report and literature review. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1171802"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Olteanu, A.O., Klimko, A., Tieranu, I., Orzan, O.A., Toma, C.V., Ionescu, E.M., Preda, C.M., and Tieranu, C.G. (2024). Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report. Medicina, 60, Erratum in Medicina\u00a02025, 61, 185. https:\/\/doi.org\/10.3390\/medicina61020185.","DOI":"10.3390\/medicina61020185"},{"key":"ref_44","unstructured":"Preuss, C.V., and Quick, J. (2026, February 18). Ixekizumab, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK431088\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1346-8138.17115","article-title":"Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study","volume":"51","author":"Valenti","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_46","first-page":"4060","article-title":"Long-term clinical efficacy and safety of ixekizumab for psoriatic patients: A single-center experience","volume":"27","author":"Burlando","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e15011","DOI":"10.1111\/exd.15011","article-title":"The impacts of biologic treatment on metabolic profiling in psoriasis","volume":"33","author":"Deng","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_48","first-page":"187","article-title":"Monocyte to high-density lipoprotein cholesterol ratio decreased in patients with psoriasis treated with ixekizumab","volume":"75","author":"Tamer","year":"2023","journal-title":"Rev. Investig. Clin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/ajd.14297","article-title":"Successful treatment of recurrent generalized pustular psoriasis of pregnancy with ixekizumab: A case report","volume":"65","author":"Temirkaynak","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/jdv.13990","article-title":"Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: An integrated analysis of two Phase III randomized studies","volume":"31","author":"Gottlieb","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/PTT.S456393","article-title":"Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania","volume":"14","author":"Bucur","year":"2024","journal-title":"Psoriasis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/ajd.14254","article-title":"Drug survival of biologics in psoriasis: An Australian multicentre retrospective study","volume":"65","author":"Ting","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s40001-022-00845-2","article-title":"Protective effect of Secukinumab on severe sepsis model rats by neutralizing IL-17A to inhibit IKB\u03b1\/NF\u03baB inflammatory signal pathway","volume":"27","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00403-024-03122-w","article-title":"Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: Data from the PURE registry","volume":"316","author":"Papp","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ijd.16915","article-title":"Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: A retrospective, multicenter cohort study in daily practice setting","volume":"63","author":"Escario","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/jdv.19782","article-title":"Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice","volume":"38","author":"Ferran","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Du, X., Yan, C., Kong, S., Che, D., Peng, B., Zhu, L., Geng, S., and Guo, K. (2023). Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1227309"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/1346-8138.16926","article-title":"Real-world retention rates and effectiveness of secukinumab in psoriasis: Results from a multicenter cohort study (RAILWAY)","volume":"50","author":"Tada","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.2147\/CCID.S445468","article-title":"Two Cases of Immune Drift Phenomena Caused by Biologic Agents for Treating Psoriasis and Atopic Dermatitis","volume":"16","author":"Ma","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_60","first-page":"e38986","article-title":"Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis","volume":"15","author":"Choi","year":"2023","journal-title":"Cureus"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"97","DOI":"10.36849\/JDD.7639","article-title":"Atopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis","volume":"23","author":"Zundell","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_62","first-page":"351","article-title":"Bimekizumab: The First FDA-Approved Dual IL-17A\/IL-17F Inhibitor for Plaque Psoriasis\u2014A Comprehensive Literature Review","volume":"15","author":"Almarhoon","year":"2025","journal-title":"Psoriasis"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"694","DOI":"10.36849\/JDD.8381","article-title":"Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment","volume":"23","author":"Abdin","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00403-024-02868-7","article-title":"Bimekizumab in psoriasis: A monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting","volume":"316","author":"Rompoti","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/ced\/llae147","article-title":"Efficacy and safety of bimekizumab in real-world psoriasis management: Data from patients who are biologic-naive vs. biologic-experienced","volume":"49","author":"Megna","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/1346-8138.17186","article-title":"Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study","volume":"51","author":"Hagino","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaad.2024.02.039","article-title":"Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2\/3 randomized trials","volume":"91","author":"Blauvelt","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"ref_70","first-page":"33","article-title":"IL-17 Class Inhibitors and Plaque Psoriasis: Not All Biologics Relapse Equally","volume":"18","author":"Issa","year":"2025","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1111\/jdv.19974","article-title":"Management of moderate to severe psoriasis with brodalumab-Real-world evidence from the LIBERO study","volume":"38","author":"Hinz","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaad.2024.01.025","article-title":"Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study","volume":"90","author":"Papp","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s13555-023-01066-z","article-title":"Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic","volume":"14","author":"Gkalpakiotis","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_74","first-page":"48","article-title":"Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short \u201cWashout\u201d Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy","volume":"31","author":"Tampouratzi","year":"2023","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/12034754231168851","article-title":"Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch","volume":"27","author":"Gaudet","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13555-023-01092-x","article-title":"Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)","volume":"14","author":"Reich","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_77","first-page":"136","article-title":"Case of Exacerbation of Psoriasis Following COVID-19 Vaccination During Treatment with Brodalumab, Which Resulted in Secondary Failure","volume":"48","author":"Tokuyama","year":"2023","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e13706","DOI":"10.1111\/cts.13706","article-title":"Risankizumab: Mechanism of action, clinical and translational science","volume":"17","author":"Pang","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3000605241229324","DOI":"10.1177\/03000605241229324","article-title":"Risankizumab, a therapeutic alternative for psoriasis in people living with HIV","volume":"52","author":"Estevinho","year":"2024","journal-title":"J. Int. Med. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/09564624231199510","article-title":"Effectiveness and safety of risankizumab in HIV patients with psoriasis: A case series","volume":"35","author":"Orsini","year":"2024","journal-title":"Int. J. STD AIDS"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e2024171","DOI":"10.5826\/dpc.1403a171","article-title":"Psoriasis with Leg Involvement as the New Difficult-To-Treat Area: A Cohort Study of Patients Treated with Risankizumab","volume":"14","author":"Bardazzi","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2358150","DOI":"10.1080\/09546634.2024.2358150","article-title":"Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: A real-life retrospective study (VESPA-Study)","volume":"35","author":"Orsini","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Ibba, L., Malagoli, P., Amoruso, F., Argenziano, G., Balato, A., Bardazzi, F., Burlando, M., Carrera, C.G., and Damiani, G. (2024). Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J. Clin. Med., 13.","DOI":"10.3390\/jcm13020495"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1111\/exd.14963","article-title":"Predictors for the effectiveness of 75\u2009mg risankizumab in treating psoriasis-A real-word evidence from a 52-week retrospective study","volume":"32","author":"Hsieh","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaad.2023.08.097","article-title":"Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry","volume":"90","author":"Strober","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/12034754231191458","article-title":"The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study","volume":"27","author":"Hamm","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2220849","DOI":"10.1080\/09546634.2023.2220849","article-title":"Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: A real-world experience from two referral centers","volume":"34","author":"Orsini","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"212594","DOI":"10.7573\/dic.212594","article-title":"Guselkumab for the treatment of psoriasis\u2014Evidence to date","volume":"8","author":"Nogueira","year":"2019","journal-title":"Drugs Context"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Marcelli, L., Belcastro, A., Talamonti, M., Paganini, C., Fico, A., Savastano, L., Di Raimondo, C., Vellucci, L., Bianchi, L., and Galluzzo, M. (2024). Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175175"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1007\/s13555-024-01245-6","article-title":"Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: A Post hoc Analysis of the VOYAGE 1 Clinical Trial","volume":"14","author":"Puig","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Megna, M., Ruggiero, A., Martora, F., Vallone, Y., Guerrasio, G., and Potestio, L. (2024). Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13092691"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/jdv.20074","article-title":"Exposure-response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis","volume":"38","author":"Soenen","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2147\/JIR.S450048","article-title":"Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment","volume":"17","author":"Yuan","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II\/III Clinical Studies in Psoriasis and Psoriatic Arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40261-023-01280-9","article-title":"Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation","volume":"43","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/1346-8138.16865","article-title":"Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations","volume":"50","author":"Jo","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2349658","DOI":"10.1080\/09546634.2024.2349658","article-title":"Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States","volume":"35","author":"Zhdanava","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2331807","DOI":"10.1080\/09546634.2024.2331807","article-title":"Successful treatment of generalized pustular psoriasis with guselkumab","volume":"35","author":"Part","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5114\/reum.2019.87620","article-title":"Tildrakizumab in the treatment of psoriasis\u2014Literature review","volume":"57","author":"Banaszczyk","year":"2019","journal-title":"Reumatologia"},{"key":"ref_100","first-page":"137","article-title":"Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada","volume":"29","author":"Cowger","year":"2024","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e15152","DOI":"10.1111\/exd.15152","article-title":"Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice","volume":"33","author":"Roustan","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ad.2023.08.019","article-title":"52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience","volume":"115","year":"2024","journal-title":"Actas Dermosifiliogr."},{"key":"ref_103","first-page":"e2023215","article-title":"Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis","volume":"13","author":"Buononato","year":"2023","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1111\/jdv.19468","article-title":"Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24\u2009weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group","volume":"37","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1177\/09564624241279489","article-title":"Effectiveness and safety of tildrakizumab in individuals with HIV and psoriasis: A case series","volume":"35","author":"Krygier","year":"2024","journal-title":"Int. J. STD AIDS"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1007\/s13555-024-01252-7","article-title":"A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice","volume":"14","author":"Burlando","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Nicolescu, A.C., Ionescu, M.-A., Constantin, M.M., Ancuta, I., Ionescu, S., Niculet, E., Tatu, A.L., Zirpel, H., and Tha\u00e7i, D. (2022). Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness. Life, 12.","DOI":"10.3390\/life12122050"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 2: Specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"16355","DOI":"10.1007\/s00210-025-04334-1","article-title":"Balancing efficacy and hepatotoxicity: A comprehensive review of oral medications in psoriasis management","volume":"398","author":"Elsisi","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ijd.70092","article-title":"Efficacy of Biologics for the Treatment of Moderate-To-Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta-Analysis","volume":"65","author":"Asahina","year":"2026","journal-title":"Int. J. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/jdv.19135","article-title":"Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients","volume":"37","author":"Mastorino","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000093852","article-title":"Excimer laser versus narrowband UVB in the treatment of psoriasis vulgaris","volume":"213","author":"Goldinger","year":"2006","journal-title":"Dermatology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1067\/mjd.2002.120454","article-title":"Efficacy of the 308-nm excimer laser for treatment of psoriasis: Results of a multicenter study","volume":"46","author":"Feldman","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clindermatol.2005.10.024","article-title":"Use of the 308-nm excimer laser for psoriasis and vitiligo","volume":"24","author":"Passeron","year":"2006","journal-title":"Clin. Dermatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2133.2006.07141.x","article-title":"Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: A comparative study","volume":"155","author":"Erceg","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0190-9622(97)80149-1","article-title":"Treatment of psoriasis with the pulsed dye laser","volume":"37","author":"Lanigan","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Odrzywo\u0142ek, W., Deda, A., Zdrada, J., Wcis\u0142o-Dziadecka, D., B\u0142o\u0144ska-Fajfrowska, B., and Wilczy\u0144ski, S. (2022). Quantitative Assessment of the Efficacy of the Nd:YAG Laser Therapy of Psoriasis. Processes, 10.","DOI":"10.3390\/pr10071404"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2011.12.015","article-title":"The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: A randomized, double-blind, intrapatient left-to-right study","volume":"66","author":"Treewittayapoom","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Nistico, S.P., Bennardo, L., Bennardo, S., Marigliano, M., Zappia, E., Silvestri, M., and Cannarozzo, G. (2022). Comparing Traditional and in Motion Nd:YAG Laser in Hair Removal: A Prospective Study. Medicina, 58.","DOI":"10.3390\/medicina58091205"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/1744666X.2023.2205640","article-title":"Lasers for the treatment of psoriasis: A systematic review","volume":"19","author":"Heidemeyer","year":"2023","journal-title":"Expert Rev. Clin. Immunol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/340\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:15:00Z","timestamp":1772082900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":120,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ph19020340"],"URL":"https:\/\/doi.org\/10.3390\/ph19020340","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]}}}